Albemarle Corporation
ALB
$93.67
+1.22%
Albemarle Corporation is one of the world's largest and most fully integrated lithium producers, converting brine deposits in Chile and the US and hard-rock spodumene from two Australian joint ventures into battery-grade lithium compounds used primarily in electric-vehicle batteries, while also operating a leading global bromine franchise for flame retardants and a Specialties chemicals business. Its scale, resource ownership, and multi-continent refining footprint (Chile, US, Australia, China) make it the closest thing to a bellwether pure-play on the lithium supply chain among Western chemical producers, distinct from diversified miners and from Chinese refiners. The current investor debate is dominated by the violent whipsaw in lithium pricing and the company's earnings volatility: a strong Q2 2026 print (revenue up 31% year over year, EPS of $3.72) briefly revived the recovery thesis, but the shares have since collapsed to fresh lows as the market discounts another leg down in lithium realizations and questions the durability of the margin recovery. Commentary has shifted from "lithium-fueled rebound" optimism earlier in the year to a debate over whether the forward earnings power embedded in consensus estimates is achievable, with the stock's roughly 52% six-month decline and deeply negative relative strength framing Albemarle as a high-beta cyclical turnaround bet rather than a momentum name.…
ALB
Albemarle Corporation
$93.67
Related headlines
Investment Opinion: Should I buy ALB Today?
Rating: Hold with a speculative accumulation bias. The core thesis is that Albemarle is a high-quality lithium asset trading at a deep discount to normalized earnings — 8.48x forward EPS of $13.90 versus 15-20x for specialty chemical peers — but the market is correctly demanding proof that those earnings are durable, and the tape (5.6% of the 52-week range, -51.72% over six months) says that proof has not arrived. The analyst consensus 'buy' (mean 1.91 across 21 analysts) and $161.78 average target imply 69% upside, but the $83.28-$225.00 range shows conviction is thin.
Supporting evidence is genuinely strong: Q2 2026 revenue grew 31.08% year over year to $1.743 billion, the fifth consecutive quarterly increase; gross margin recovered to 33.86% with a 27.5% net margin; trailing free cash flow is $1.342 billion with Q2 2026 FCF of $638 million on just $71.7 million of capex; debt-to-equity is 0.346 with a 2.23 current ratio after repaying $1.278 billion of debt in Q1 2026; and the 1.75x price-to-book sits near the low end of the company's own history versus 4.86x at the 2021 peak. The PEG of 0.51 and 3.24x PS — at the bottom of a five-year 5.5x-30.6x band — reinforce that the stock is priced for a prolonged glut.
Three risks could invalidate the thesis: a lithium price relapse that compresses gross margin back toward 8.99%, a consensus EPS cut below the $11.96 low estimate, and a decisive break of the $88.01 52-week low that triggers capitulation selling. This Hold would upgrade to Buy if the stock reclaims the $120-$135 resistance band or if Q3 2026 gross margin holds above 30% with FY EPS tracking toward $13.90; it would downgrade to Sell on a close below $88.01 or a dividend cut. Verdict: undervalued relative to its own history and normalized earnings, but fairly-to-fully priced for the risk that the lithium recovery stalls — a value opportunity only for investors who can tolerate a 1.359 beta and a potential 13% further downside to the bear target.
Sign up to view all
ALB 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Albemarle Corporation's 12-month outlook, with a consensus price target around $156.35 and implied upside of +66.9% versus the current price.
Average Target
$156.35
0 analysts
Implied Upside
+66.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$83 - $211
Analyst target range
Coverage is robust with 21 analysts, and the consensus recommendation is "buy" with a mean rating of 1.91 (where 1.0 is a strong buy and 5.0 a strong sell), indicating a clearly bullish tilt despite the price collapse. The average target price of $161.78 implies roughly 69% upside from the current $95.48 — an unusually large gap that reflects either significant analyst conviction in the lithium recovery or stale targets that have not yet been cut to reflect the recent deterioration. The distribution of recent ratings shows a split house: Citigroup, UBS, and BofA carry Buy ratings, RBC and Scotiabank are Outperform, while JPMorgan and Morgan Stanley sit at Neutral/Equal Weight and Evercore is In Line — a pattern of bullish sell-side conviction offset by cautious bulge-bracket coverage.
The target range is extraordinarily wide, from a low of $83.28 (about 13% below the current price) to a high of $225.00 (roughly 136% above), a spread of nearly 170% that signals very low conviction and high uncertainty about lithium price trajectories. The high target implicitly assumes a full lithium cycle recovery with margin expansion back toward 2022-2023 peaks and multiple re-rating, while the low target prices in continued lithium weakness, margin compression, and a break below the 52-week low. Notably, no analyst has downgraded in the recent ratings feed — actions are all reiterations — suggesting the sell-side is holding its ground even as the stock makes new lows, a divergence that historically resolves either through a sharp rally or through a wave of capitulation downgrades; the consensus FY EPS estimate of $13.90 (range $11.96-$16.49) and revenue estimate of $7.40 billion will be the key battleground.
Drowning in data?
Find the real signal!
Bulls vs Bears: ALB Investment Factors
The bear case currently has stronger near-term evidence: the stock is pinned at 5.6% of its 52-week range, down 51.72% over six months, and underperforming the S&P 500 by 59.2 points over that window, with momentum accelerating to the downside. The bull case rests on genuinely impressive fundamentals — 31.08% revenue growth, 33.86% gross margin, $1.342 billion of trailing FCF, and an 8.48x forward PE — but those numbers describe two quarters of a commodity upswing, not a proven earnings base. The single most important tension is whether consensus FY EPS of $13.90 is achievable: at 8.48x forward earnings the market is pricing roughly a 40-55% haircut to that estimate, so if lithium realizations hold, the stock is deeply undervalued, but if consensus must be cut toward the $11.96 low end or below, the 'cheap' multiple is an illusion. Until the shares reclaim the $120-$135 zone where August-September bounces failed, the tape argues the market believes the latter.
Bullish
- Forward PE of 8.5x prices deep skepticism: At $95.48, ALB trades at just 8.48x consensus FY EPS of $13.90, a 40-55% discount to the roughly 15-20x typical for specialty chemical peers. The PEG ratio of 0.51 and price-to-book of 1.75x (versus 4.86x at the 2021 peak) suggest the market has already discounted a substantial haircut to normalized earnings.
- Revenue growth accelerating for five quarters: Q2 2026 revenue of $1.743 billion grew 31.08% year over year and rose sequentially from $1.429 billion in Q1 2026, the strongest growth rate in the dataset. Revenue has climbed for five consecutive quarters from the Q1 2025 trough of $1.077 billion, supporting the thesis that the lithium down-cycle has troughed.
- Margin re-rating and strong free cash flow: Gross margin recovered from 8.99% in Q3 2025 to 33.86% in Q2 2026, with net income of $480 million (27.5% net margin) and operating margin of 25.98%. Q2 2026 alone generated $638 million of free cash flow on $710 million of operating cash flow against just $71.7 million of capex, versus negative FCF of -$127 million a year earlier.
- Balance sheet deleveraging with ample liquidity: Debt-to-equity is a modest 0.346 and the current ratio is a healthy 2.23, while the company repaid $1.278 billion of debt in Q1 2026 and still paid $89 million in quarterly dividends. Trailing free cash flow of $1.342 billion gives ALB genuine capacity to weather a prolonged lithium price slump without a dilutive equity raise.
Bearish
- Falling-knife technical breakdown: At $95.48 the stock sits at just 5.6% of its 52-week range ($88.01-$221.00), roughly 57% below the high, with a maximum drawdown of -55.72%. It is down 12.78% in one month and 20.95% in three months, with the one-month decline steeper than the three-month pace — deceleration, not stabilization, with no higher-low structure.
- Earnings power entirely dependent on two quarters: Trailing-twelve-month figures still show a net margin of -9.93%, operating margin of 1.82% and EPS of -$0.03, meaning the headline profitability rests solely on Q1-Q2 2026. A 33.86% gross margin that collapsed to 8.99% within three quarters is commodity-price leverage, not structural pricing power — any lithium relapse compresses margins back toward breakeven.
- Massive relative underperformance versus market: ALB trails the S&P 500 by 14.0 points over one month, 23.6 points over three months and 59.2 points over six months, while SPY gained 1.22% and 2.69% over the one- and three-month windows. This is idiosyncratic de-rating, not market beta, and the 1.359 beta amplifies drawdowns (a 10% market decline implies roughly a 13.6% ALB move).
- Extraordinary analyst target dispersion: Targets range from $83.28 (13% below the current price) to $225.00 (136% above), a spread of nearly 170% that signals very low conviction on lithium price trajectories. The $161.78 average may be stale relative to the recent collapse, and the split house (JPMorgan and Morgan Stanley at Neutral) leaves room for capitulation downgrades.
ALB Technical Analysis
Albemarle is in a pronounced, sustained downtrend that has overwhelmed its marginal one-year gain: the stock is up just 0.20% over 12 months but down 33.66% year-to-date and 51.72% over six months, a profile of a failed rally rolling over rather than a durable uptrend. At $95.48, the shares sit at roughly 5.6% of the 52-week range (range of $88.01 to $221.00), effectively pinned near the 52-week low and about 57% below the 52-week high — positioning that signals persistent distribution and momentum-driven selling rather than a value floor, with the falling-knife risk elevated given the absence of any higher-low structure. The maximum drawdown of -55.72% over the period confirms the severity of the de-rating.
Short-term momentum is uniformly negative and accelerating to the downside: the stock is down 12.78% over one month and 20.95% over three months, with the one-month decline steeper than the three-month pace, indicating deceleration rather than stabilization. This is a clear divergence from the longer-term trend — the trailing 12-month change is barely positive (+0.20%) while every shorter window is deeply negative, a classic pattern of a rally exhausting and reversing into a lower regime. Relative strength confirms the underperformance is idiosyncratic rather than market-driven: ALB trails the S&P 500 by 14.0 points over one month, 23.6 points over three months, and 59.2 points over six months, while SPY itself gained 1.22% and 2.69% over the one- and three-month windows. Volume of roughly 2.22 million shares and a short ratio of 4.53 days suggest short interest is meaningful but not extreme, leaving room for further pressure without a squeeze catalyst.
Key technical levels are well defined: support sits at the 52-week low of $88.01, roughly 7.8% below the current $95.48, and a decisive break below that level would signal capitulation and open the door to a new leg lower with no visible historical floor. Resistance is anchored at the 52-week high of $221.00, but the more relevant near-term hurdle is the $120-$135 zone where the stock repeatedly failed during its August-September bounce attempts; reclaiming that band would be the first evidence of a trend change. With a beta of 1.359, the stock is roughly 36% more volatile than the market, meaning position sizing should assume amplified drawdowns — a 10% market decline would historically imply a roughly 13.6% move in ALB, and the -2.75% single-day drop on the latest session underscores that sensitivity.
Beta
1.36
1.36x market volatility
Max Drawdown
-57.1%
Largest decline past year
52-Week Range
$88-$221
Price range past year
Annual Return
-3.8%
Cumulative gain past year
| Period | ALB Return | S&P 500 |
|---|---|---|
| 1m | -17.4% | -1.0% |
| 3m | -18.4% | +2.9% |
| 6m | -50.3% | +6.5% |
| 1y | -3.8% | +13.1% |
| ytd | -34.9% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALB Fundamental Analysis
The revenue trajectory has inflected sharply upward after a prolonged trough: Q2 2026 revenue of $1.743 billion grew 31.08% year over year versus $1.330 billion in Q2 2025, and rose sequentially from $1.429 billion in Q1 2026, marking the strongest growth rate in the dataset. The Energy Storage segment generated $1.277 billion of that total (roughly 73%) while Specialties contributed $423 million, confirming that lithium — not bromine — is the swing factor driving the entire investment case. The multi-quarter arc is one of recovery from a deep trough: revenue bottomed near $1.077 billion in Q1 2025 and has climbed for five consecutive quarters, which supports the bull argument that the lithium down-cycle has troughed, though the market's skepticism reflects concern that pricing, not volume, remains the fragile variable.
Profitability has swung dramatically from losses to solid margins: Q2 2026 net income was $480 million (a 27.5% net margin) with gross margin of 33.86% and operating margin of 25.98%, a stark contrast to Q4 2025's net loss of $414 million and 14.20% gross margin, and to Q3 2024's catastrophic -$1.069 billion loss with negative gross margin. The gross margin progression — 8.99% in Q3 2025, 14.20% in Q4 2025, 35.06% in Q1 2026, 33.86% in Q2 2026 — shows a violent re-rating of unit economics that is characteristic of a commodity producer levered to spot pricing rather than a structurally improving cost position. The trailing-twelve-month figures still carry the scars of the downturn (net margin -9.93%, operating margin 1.82%, EPS -$0.03), meaning the headline profitability is entirely dependent on the most recent two quarters holding; any lithium price relapse would rapidly compress these margins back toward breakeven.
Balance sheet and cash generation are the strongest part of the story: debt-to-equity is a modest 0.346, the current ratio is a healthy 2.23, and trailing free cash flow is $1.342 billion, with Q2 2026 alone generating $638 million of FCF on $710 million of operating cash flow against just $71.7 million of capex — a dramatic improvement from the negative FCF of -$127 million in Q2 2025 and -$355 million in Q4 2024. The company also repaid $1.278 billion of debt in Q1 2026 while still paying $89 million in quarterly dividends, demonstrating genuine deleveraging capacity. However, ROE of -5.36% and ROA of 3.17% remain weak on a trailing basis, and the 2.15% dividend yield with a negative payout ratio (-0.70) reflects trailing losses rather than a sustainable distribution — investors should treat the dividend as dependent on the lithium recovery persisting.
Quarterly Revenue
$1.7B
2026-06
Revenue YoY Growth
+31.1%
YoY Comparison
Gross Margin
33.9%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALB Overvalued?
Because trailing net income is negative (EPS of -$0.03, trailing PE of -24.6x), the PE ratio is not a valid primary metric; instead, the PS ratio of 3.24x and EV/Sales of 2.45x are the appropriate anchors, supplemented by the forward PE of 8.48x, which is the single most important number in the valuation debate. The gap between the meaningless trailing PE and the 8.48x forward multiple implies the market expects a full normalization of earnings — consensus FY EPS of $13.90 against a $95.48 price — but the stock's collapse suggests investors are discounting that estimate heavily, effectively pricing in a substantial haircut to forward earnings power. The PEG ratio of 0.51 and price-to-book of 1.75x suggest the stock is cheap on normalized metrics if the earnings recovery materializes.
Relative to the specialty chemicals sector, Albemarle screens cheap on forward earnings but expensive on asset-based and cash-flow measures: the 8.48x forward PE is well below the roughly 15-20x typical for specialty chemical peers, a discount of 40-55%, while the 3.24x PS and 32.8x EV/EBITDA are elevated versus sector norms because current EBITDA is depressed relative to normalized levels. The 1.75x price-to-book is near the low end of the company's own history and below the specialty chemicals average, reflecting the market's skepticism about the durability of lithium margins. The discount is arguably justified by the commodity-price dependency and earnings volatility — a 33.86% gross margin that collapsed to 8.99% within three quarters is not the stable pricing power investors pay premium multiples for — but the forward PE implies the market has overshot to the downside if consensus is even roughly right.
Historical context is instructive: Albemarle's PS ratio has ranged from roughly 5.5x (Q2 2025) to 30.6x (Q4 2021) over the past five years, and the current 3.24x sits at the very bottom of that band, below even the 2025 trough readings of 5.5-7.3x. Similarly, price-to-book of 1.75x compares with 4.86x at the end-2021 peak and 0.72x at the mid-2025 trough, placing the stock in the lower quartile of its own valuation history. This positioning suggests the market is pricing in either a prolonged lithium glut or balance-sheet deterioration; if neither materializes, the historical band implies meaningful re-rating potential, but the stock's own history also warns that these lows can persist for multiple quarters during commodity down-cycles.
PE
-24.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
32.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by earnings concentration and commodity leverage. Trailing-twelve-month net margin is -9.93% and EPS -$0.03, so the entire profitability story rests on Q1-Q2 2026, when gross margin swung from 8.99% in Q3 2025 to 33.86% in Q2 2026 — a 25-point move in three quarters that reflects spot lithium pricing rather than a durable cost advantage. Energy Storage generated $1.277 billion of Q2 2026's $1.743 billion revenue (roughly 73%), so a single product and a single commodity price drive the investment case, and the dividend's -0.70 payout ratio means the 2.15% yield is not covered by trailing earnings. Mitigants exist — debt-to-equity of 0.346, current ratio of 2.23, $1.342 billion trailing FCF and $1.278 billion of Q1 2026 debt repayment — but they buy time rather than protect margins.
Market and competitive risks center on valuation compression and cyclicality. The 8.48x forward PE is a 40-55% discount to specialty chemical peers, but that discount is arguably deserved given a gross margin that collapsed from 33.86% to 8.99% within three quarters; the 32.8x EV/EBITDA is elevated because current EBITDA is depressed, and the 3.24x PS sits at the very bottom of a five-year range of roughly 5.5x-30.6x, meaning the stock can stay cheap for multiple quarters in a commodity down-cycle. With a beta of 1.359, ALB is roughly 36% more volatile than the market, and the -2.75% single-day drop on the latest session underscores that sensitivity; Chinese refining capacity and EV demand deceleration remain structural threats to lithium realizations. The 170% spread in analyst targets ($83.28-$225.00) is itself a risk signal — it means the sell-side has no consensus on the commodity's direction.
In a worst-case scenario, lithium prices roll over again, Q3/Q4 2026 margins compress back toward the 8.99% Q3 2025 level, consensus FY EPS of $13.90 is cut toward or below the $11.96 low estimate, and the sell-side capitulates with downgrades. The stock breaks the $88.01 52-week low — only 7.8% below the current $95.48 — and with no visible historical floor, the analyst low target of $83.28 implies roughly -13% from here, while a retest of the -55.72% maximum drawdown profile from the recent high would be far more severe. Realistically, an investor could lose 13% to the $83.28 bear target and 8% to the $88.01 support in a mild adverse case, with a break below $88 opening a new leg lower toward the mid-$70s.
FAQ
Ranked by severity: first, commodity price risk — a lithium relapse would compress gross margin from 33.86% back toward the 8.99% seen in Q3 2025, gutting the 8.48x forward PE thesis and forcing EPS cuts below the $11.96 low estimate. Second, technical/momentum risk — at $95.48 the stock is only 7.8% above its $88.01 52-week low, and a break would open a new leg lower with no visible floor toward the $83.28 bear target. Third, earnings concentration — Energy Storage is roughly 73% of revenue ($1.277 billion of $1.743 billion in Q2 2026), so a single product and price drive the entire case, and trailing net margin is still -9.93%. Fourth, dividend risk — the 2.15% yield carries a -0.70 payout ratio, and a cut would remove a valuation support; the 1.359 beta also means a 10% market decline historically implies a 13.6% ALB move.
The 12-month forecast splits into three scenarios: a 25% bull case targeting $161-$225 (lithium prices grind higher, gross margin holds above 30%, FY EPS near $13.90, multiple re-rates toward 15-20x), a 50% base case targeting $110-$145 (lithium range-bound, FY EPS of $11-$13, stock bases above $88 and partially retraces), and a 25% bear case targeting $75-$88 (margin compression toward 8.99%, EPS cuts below $11.96, break of the 52-week low toward the $83.28 analyst low). The base case is most likely, and its key assumption is that lithium realizations hold roughly flat, keeping gross margin in the 25-34% range and free cash flow positive. Note the analyst average target of $161.78 sits at the low end of the bull range, implying the sell-side is more optimistic than the probability-weighted outcome.
On normalized metrics ALB screens undervalued: the 8.48x forward PE is a 40-55% discount to the 15-20x typical for specialty chemical peers, the PEG is 0.51, and price-to-book of 1.75x compares with 4.86x at the 2021 peak and 0.72x at the mid-2025 trough. The 3.24x PS ratio sits at the very bottom of a five-year range of roughly 5.5x-30.6x, below even the 2025 trough readings. However, the trailing PE of -24.6x is meaningless given negative EPS of -$0.03, and the 32.8x EV/EBITDA is elevated because current EBITDA is depressed. The market is paying a discount because it expects a prolonged lithium glut or further earnings deterioration — if neither materializes, the historical band implies meaningful re-rating, but the stock's own history shows these lows can persist for multiple quarters.
From a risk/reward perspective, ALB offers an asymmetric setup only if you believe lithium prices hold: the stock trades at 8.48x forward EPS of $13.90 with a $161.78 average analyst target implying 69% upside, against a $83.28 bear target implying roughly 13% downside. The fundamentals support the bull case — 31.08% revenue growth, 33.86% gross margin, $1.342 billion trailing FCF and debt-to-equity of 0.346 — but the tape is brutal, with the stock at 5.6% of its 52-week range and down 51.72% over six months. The biggest downside risk is a lithium relapse that compresses gross margin back toward 8.99% and forces EPS cuts below $11.96. It is a good buy for patient, risk-tolerant investors building a position in tranches with a stop below $88.01, but not for anyone who needs near-term momentum or income certainty.
ALB is best suited to a long-term holding period of at least 18-24 months, because the thesis depends on a lithium cycle recovery that the stock's own history shows can take multiple quarters to materialize — the PS ratio has stayed at trough levels for extended periods before. Short-term trading is treacherous: beta of 1.359, a -55.72% maximum drawdown, a -2.75% single-day drop on the latest session, and a 4.53-day short ratio mean volatility is amplified and there is no squeeze catalyst. The 2.15% dividend yield is not a reason to hold given the -0.70 payout ratio, so total return depends entirely on capital appreciation. A concrete approach: build the position in tranches over 6-12 months with a hard stop below $88.01, and reassess after two consecutive quarters of gross margin above 30%.